Eastwood Bio-Medical Canada Inc (TSE:EBM)
:EBM
Want to see TSE:EBM full AI Analyst Report?
Top Page
Eastwood Bio-Medical Canada
(EBM)
Select Model
Select Model
Rating:40Underperform
Price Target:
C$0.62
▼(-22.75% Downside)
Action:Downgraded
Date:05/15/26
The score is primarily driven by weak financial performance: persistent heavy losses, declining TTM revenue, and negative equity, which raise profitability and solvency concerns. Technicals add additional pressure with the stock trading below key moving averages and negative MACD, though a low Stochastic suggests potential near-term oversold conditions. Valuation provides limited support because the negative P/E reflects ongoing losses and there is no dividend yield data.
Positive Factors
High gross margin (~63%)
A ~63% gross margin indicates durable product-level economics and pricing power for core supplements. Sustained gross margin provides room to invest in R&D, marketing and distribution to scale revenue and supports longer-term path to operating leverage if SG&A growth is controlled.
Negative Factors
Deep and persistent losses
Persistent large net losses and negative operating margins erode retained capital and limit the firm's ability to self-fund growth. Over time this constrains reinvestment in product development and distribution expansion and raises the need for external funding or structural cost reductions.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin (~63%)
A ~63% gross margin indicates durable product-level economics and pricing power for core supplements. Sustained gross margin provides room to invest in R&D, marketing and distribution to scale revenue and supports longer-term path to operating leverage if SG&A growth is controlled.
Read all positive factors
Eastwood Bio-Medical Canada (EBM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$48.22M
Dividend YieldN/A
Average Volume (3M)3.49K
Price to Earnings (P/E)―
Beta (1Y)-0.06
Revenue Growth0.53%
EPS Growth29.69%
CountryCA
EmployeesN/A
SectorConsumer Defensive
Sector Strength42
IndustryFood Distribution
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding68,885,970
10 Day Avg. Volume3,055
30 Day Avg. Volume3,488
Financial Highlights & Ratios
PEG Ratio5.31
Price to Book (P/B)-29.59
Price to Sales (P/S)61.66
P/FCF Ratio2.50K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eastwood Bio-Medical Canada Business Overview & Revenue Model
Company Description
Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. It distributes Eleotin that provide natural remedies for metabolic disorders, such as blood glucose di...
How the Company Makes Money
Eastwood Bio-Medical Canada (EBM) generates revenue primarily through the sale of its Eleotin-branded natural health supplements. These products are distributed through various channels, including online stores, retail partners, and direct custome...
Eastwood Bio-Medical Canada Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
30
Negative
| Breakdown | Jan 2026 | Jan 2025 | Oct 2023 | Oct 2022 | Jan 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 782.08K | 702.08K | 867.94K | 1.30M | 981.05K |
| Gross Profit | 506.03K | 454.39K | 440.51K | 902.74K | 458.37K |
| EBITDA | -309.73K | -342.05K | -410.58K | -32.33K | -495.50K |
| Net Income | -332.77K | -455.87K | -546.60K | -160.58K | -611.34K |
Balance Sheet | |||||
| Total Assets | 218.77K | 274.29K | 489.14K | 584.53K | 691.12K |
| Cash, Cash Equivalents and Short-Term Investments | 17.70K | 0.00 | 18.45K | 39.84K | 20.87K |
| Total Debt | 78.01K | 79.61K | 23.08K | 62.25K | 31.35K |
| Total Liabilities | 1.85M | 1.57M | 1.33M | 878.73K | 835.44K |
| Stockholders Equity | -1.63M | -1.30M | -840.80K | -294.20K | -144.32K |
Cash Flow | |||||
| Free Cash Flow | 19.30K | -15.22K | -16.89K | -7.30K | -121.79K |
| Operating Cash Flow | 19.30K | -15.22K | -16.89K | -4.29K | -116.21K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -3.00K | -5.57K |
| Financing Cash Flow | -211.00 | -4.62K | -4.50K | 26.27K | 20.00K |
Eastwood Bio-Medical Canada Technical Analysis
Positive
0.80
Price Trends
0.70
Negative
0.73
Negative
0.67
Positive
Market Momentum
-0.01
Negative
52.00
Neutral
96.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EBM, the sentiment is Positive. The current price of 0.8 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.70, and above the 200-day MA of 0.67, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 52.00 is Neutral, neither overbought nor oversold. The STOCH value of 96.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EBM.
Eastwood Bio-Medical Canada Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
50 Neutral | C$66.92M | -10.05 | -19.76% | ― | -100.00% | 87.93% | |
45 Neutral | C$22.88M | -9.48 | 3086.87% | ― | -46.50% | 1.32% | |
41 Neutral | C$30.23M | -12.93 | 72.34% | ― | ― | 26.83% | |
41 Neutral | C$38.32M | -16.88 | -434.25% | ― | ― | 8.62% | |
40 Underperform | C$48.22M | -498.55 | ― | ― | 0.53% | 29.69% |
* Consumer Defensive Sector Average
TSE:EBM
Eastwood Bio-Medical Canada
0.70
0.30
75.00%
TSE:ARCH
Arch Biopartners
0.45
-1.31
-74.57%
TSE:ADK
Diagnos
0.19
-0.05
-22.92%
TSE:ATLE
Willow Biosciences Inc
0.19
0.01
5.71%
TSE:ZYUS
ZYUS Life Sciences
0.50
-0.24
-32.43%
TSE:SONA
Sona Nanotech Inc
0.33
-0.04
-12.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.